Oruka Therapeutics (ORKA) total liabilities

Total liabilities · fiscal 2025
$16.69M

Oruka Therapeutics (ORKA) had total liabilities of $16.69M at the end of fiscal 2025 (December 31, 2025). That is 20.9% higher than the $13.80M of fiscal 2024. Figures as of 19 Nov 2026, 00:22 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$16.69M
Change on fiscal 2024
+20.9%
Growth, 5 years
+33.7% a year
Growth, 10 years
+27.2% a year
Highest on record
$16.69Mfiscal 2025
Lowest on record
$305.00Kfiscal 2012
Fiscal years on record
162010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Oruka Therapeutics total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 33.7% a year; over ten years the rate was 27.2% a year. Across the 16 fiscal years on record (2010–2025), the highest was $16.69M in fiscal 2025 and the lowest $305.00K in fiscal 2012.

History · 16 fiscal years

Total liabilities by fiscal year

Oruka Therapeutics total liabilities, year by year

Oruka Therapeutics (ORKA) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$16.69M 20.9% up
2024$13.80M 1,540.7% up
2023$841.00K 40.4% down
2022$1.41M 63.6% down
2021$3.88M 0.7% down
2020$3.91M 322.0% up
2019$926.00K 16.8% up
2018$793.00K 62.1% down
2017$2.09M 14.2% down
2016$2.44M 61.9% up
2015$1.50M 8.1% up
2014$1.39M 7.5% down
2013$1.50M 392.8% up
2012$305.00K 60.4% down
2011$770.00K 44.4% down
2010$1.39M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Oruka Therapeutics and comparable companies
CompanyTotal liabilitiesFiscal year
Immunovant IMVT$104.42M2026
Axsome Therapeutics AXSM$601.51M2025
Chemed CHE$558.78M2025
Oruka Therapeutics ORKA$16.69M2025
Arrowhead Pharmaceuticals ARWR$1.69B2026
MSA Safety MSA$1.19B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ORKA

Oruka Therapeutics, figure by figure

Oruka Therapeutics (ORKA) overview: price, valuation and scorecardAll health care companies by market value

Oruka Therapeutics total liabilities: questions and answers

How large are Oruka Therapeutics's total liabilities?

Oruka Therapeutics (ORKA) had total liabilities of $16.69M at the end of fiscal 2025 (December 31, 2025). That is 20.9% higher than the $13.80M of fiscal 2024.

What is the growth rate of Oruka Therapeutics's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 33.7% a year; over ten years the rate was 27.2% a year.

What are the highest and lowest total liabilities figures on record for Oruka Therapeutics?

Across the 16 fiscal years on record (2010–2025), the highest was $16.69M in fiscal 2025 and the lowest $305.00K in fiscal 2012.

How is Oruka Therapeutics's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Oruka Therapeutics it is on record here for 16 fiscal years, 2010 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Oruka Therapeutics (ORKA) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/ORKA/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.